These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 18634163

  • 1. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B.
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [Abstract] [Full Text] [Related]

  • 2. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J, 990757 Study Group.
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [Abstract] [Full Text] [Related]

  • 3. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 4. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 5. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
    Karanikolas G, Charalambopoulos D, Vaiopoulos G, Andrianakos A, Rapti A, Karras D, Kaskani E, Sfikakis PP.
    Rheumatology (Oxford); 2008 Sep; 47(9):1384-8. PubMed ID: 18603660
    [Abstract] [Full Text] [Related]

  • 6. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 7. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.
    Cohen SB, Woolley JM, Chan W, Anakinra 960180 Study Group.
    J Rheumatol; 2003 Feb; 30(2):225-31. PubMed ID: 12563672
    [Abstract] [Full Text] [Related]

  • 8. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G.
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

  • 10. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B.
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [Abstract] [Full Text] [Related]

  • 11. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 12. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, 20000223 Study Group.
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [Abstract] [Full Text] [Related]

  • 14. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 15. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
    Sanmartí R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N, Rodriguez-Cros JR, Erra A, Reina D, Gratacós J.
    Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
    [Abstract] [Full Text] [Related]

  • 16. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P, Esselens G, Westhovens R.
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [Abstract] [Full Text] [Related]

  • 17. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 18. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 19. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP.
    Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.